From target identification and molecular design to patient stratification and clinical trial optimization, artificial intelligence (AI) is showing remarkable promise in accelerating drug discovery and ...

Improved content discoverability via Reaxys® Medicinal Chemistry combined with data integration capabilities allow chemists to identify and optimize promising lead candidates Elsevier, a world-leading ...

Clinical trials for drug development are notoriously slow and expensive, and only a small fraction of drug candidates end up being approved by the regulatory authorities. The extensive bottlenecks in ...

Interested in finding a better way to develop drugs to treat amyotrophic lateral sclerosis (ALS), Northeastern researcher Jeffrey Agar and a team of scientists came up with a technique that improves ...

BullFrog AI Holdings, Inc. has introduced bfLEAP™, an advanced platform designed to enhance the drug development process in biopharma by utilizing AI and machine learning for greater predictive ...

Located at the cellular interface, membrane proteins play critical regulatory roles in the signaling between a cell and its interacting environment, making them popular and ideal drug targets.

Traditionally, developing a new drug takes many years and requires a massive financial investment, often involving significant risk and a high likelihood of failure. AI models trained on extensive ...

Revvity offers comprehensive solutions designed to help accelerate laboratory workflows, assisting researchers meet targets faster and bring new therapies to market sooner. Our integrated approach ...

Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

SHENZHEN, China, Sept. 9, 2025 /PRNewswire/ -- XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery ...

In this interview, Alastair Carrington, director at Atelerix, outlines how hydrogel-based preservation technology can enable ...